At the 11th International Congress on Anti-Cancer Treatment, in Paris, France, developers reported on successful pre-clinical trials of nitric oxide (NO) derivatives of the two drugs.
The in vitro trials involved colon and pancreatic cancer cells. During the trials, aspirin and sulindac were compared with the NO derivatives.
The derivatives were found to be 2500-times as effective at reducing growth of the cells as were the parent drugs, researchers reported.
Developers, NicOx of Sophia-Antipolis, France, now hope to move to animal trials followed by human trials.
|The NO derivatives were 2500-times more effective than the parent drugs in reducing cancer cell growth.
|11th International Congress on Anti-Cancer Treatment|
Researcher Professor Basil Rigas, of Rockefeller University, New York, USA, said, "Aspirin and sulindac are prototypical colon chemopreventive agents.
"However, their toxicity and attendant mortality hamper their wide application, necessitating the search for safe alternatives.
"Both the superior efficacy and safety showed by NicOx NO-releasing compounds at this pre-clinical stage suggest that NO-aspirin and sulindac derivatives could become excellent drugs for such an application."
Report Copyright: Englemed Health News at http://www.internationalmedicalnews.com